Lilly Eli & Co - LLY STOCK NEWS

Eli Lilly and Company (NYSE: LLY) has declared a third-quarter dividend of $0.74 per share on its outstanding common stock. The dividend is scheduled for payment on September 10, 2020, to shareholders of record by the close of business on August 14, 2020. This dividend announcement reflects Lilly's commitment to returning value to its shareholders and maintaining robust financial health.

Eli Lilly has launched the Know Before the Low initiative to increase awareness and preparedness for low blood sugar emergencies among the 34 million Americans with diabetes. The program aims to educate individuals on recognizing symptoms and developing rescue plans with their support networks. Crystal Bowersox, a diabetes ambassador, emphasizes the importance of having a support system. Resources are available at KnowBeforeTheLow.com to help people understand low blood sugar signs and prepare effective emergency responses.

Boehringer Ingelheim and Eli Lilly announced full results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials, evaluating Jardiance® (empagliflozin) in chronic heart failure patients. The trials showed no significant improvement in exercise ability with Jardiance compared to placebo, with median six-minute walk test increases of 13.5 meters and 10.0 meters for Jardiance against 18.0 and 5.0 meters for placebo, respectively. However, exploratory analyses indicated quality of life improvements. Safety profiles were consistent across diabetic and non-diabetic participants.

Eli Lilly's Emgality has shown significant results in reducing the total pain burden for patients with episodic and chronic migraine. In a recent study, patients using Emgality experienced an average of 68.6 fewer severity-weighted hours of pain per month for episodic migraine and 102.6 fewer hours for chronic migraine compared to baseline. This analysis was presented at major neurology conferences, marking Emgality as the first CGRP medication to be assessed on total pain burden, enhancing understanding of migraine management.

Eli Lilly and Company (NYSE: LLY) revealed that less than 30% of migraine sufferers are using recommended prescription medications, according to the OVERCOME study. The study, involving over 21,000 participants, aims to identify barriers in migraine treatment. Key findings showed that among individuals with significant migraine-related disability, 63% sought care, but only 28% completed all three critical steps (seeking care, receiving a diagnosis, and taking medication). The research highlights the ongoing challenges in migraine care, including stigma and accessibility issues.

Eli Lilly and Company (NYSE: LLY) announced that Verzenio® (abemaciclib) combined with standard adjuvant endocrine therapy has met its primary endpoint of invasive disease-free survival, significantly reducing breast cancer recurrence risk in high-risk hormone receptor-positive (HR+), HER2- early breast cancer. This success, revealed in a Phase 3 monarchE study interim analysis, makes Verzenio the only CDK4 & 6 inhibitor to achieve such results. Lilly plans to present these findings at a medical meeting later this year and aims to submit data to regulatory authorities by the end of 2020.

The U.S. FDA has approved Lyumjev™ (insulin lispro-aabc injection) from Eli Lilly (NYSE: LLY), a rapid-acting insulin for adults with type 1 and type 2 diabetes. Lyumjev enhances glycemic control by mimicking natural insulin absorption, effectively reducing post-meal blood sugar spikes. The approval is based on Phase 3 studies, PRONTO-T1D and PRONTO-T2D, showing that Lyumjev outperforms Humalog in lowering A1C levels at 26 weeks. Lyumjev will be priced similarly to Humalog and is part of the Lilly Insulin Value Program, allowing affordable access to patients.

Eli Lilly and Company (NYSE: LLY) initiated a Phase 3 trial to assess the efficacy and safety of baricitinib in hospitalized adults with COVID-19. This randomized, double-blind, placebo-controlled study aims to enroll 400 patients across the U.S., Europe, and Latin America. Key endpoints include mortality rates and the requirement for mechanical ventilation by Day 28. Baricitinib is currently approved for rheumatoid arthritis and may mitigate COVID-19 complications by reducing hyperinflammation. Results are anticipated in the coming months as Lilly combats the pandemic and supports ongoing related research.

On June 13, 2020, Eli Lilly (NYSE: LLY) announced that Trulicity® (dulaglutide) exhibited significantly higher adherence and persistence compared to semaglutide and exenatide in type 2 diabetes patients. Presented at the ADA's 80th Scientific Sessions, the study utilized U.S. claims data, showing that after six months, 59.7% of Trulicity users adhered to treatment, compared to 42.7% for semaglutide and 58.1% versus 40.3% for exenatide. Moreover, treatment discontinuation rates were lower for Trulicity at 30.8%, compared to 40.8% and 32.1% for its competitors.